drugset
drugset / Trial / NCT02086175

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

NCT02086175 ↗

Phase 2 Completed 25 enrolled Dana-Farber Cancer Institute HiberCell, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).

Timeline

Start
2014-12
Primary completion
2019-07-11
Completion
2021-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Imprime PGG Other / unclassified 4 mg/kg Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

indolent B-cell non-Hodgkin lymphoma